Storage time affects umbilical cord blood viability

Guttridge, M. G.; Soh, Teck Guan; Belfield, Heli; Sidders, Chris; Watt, Suzanne M.

doi:10.1111/trf.12481

Cited by 28 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, the first cautious attempts to expand one of the grafts before dCB transplantation have significantly reduced the time to neutrophil recovery [25][26][27][28]32], although platelet recovery has remained substantially delayed when compared to current rather than historical transplant outcomes [33].…”

Section: Introductionmentioning

confidence: 99%

Thrombopoietin Treatment of One Graft in a Double Cord Blood Transplant Provides Early Platelet Recovery While Contributing to Long-Term Engraftment in NSG Mice

Brand

et al. 2015

Stem Cells and Development

Self Cite

View full text Add to dashboard Cite

Human cord blood (CB) hematopoietic stem cell (HSC) transplants demonstrate delayed early neutrophil and platelet recovery and delayed longer term immune reconstitution compared to bone marrow and mobilized peripheral blood transplants. Despite advances in enhancing early neutrophil engraftment, platelet recovery after CB transplantation is not significantly altered when compared to contemporaneous controls. Recent studies have identified a platelet-biased murine HSC subset, maintained by thrombopoietin (TPO), which has enhanced capacity for short-and long-term platelet reconstitution, can self-renew, and can give rise to myeloid-and lymphoidbiased HSCs. In previous studies, we have shown that transplantation of human CB CD34+ cells precultured in TPO as a single graft accelerates early platelet recovery as well as yielding long-term repopulation in immunedeficient mice. In this study, using a double CB murine transplant model, we investigated whether TPO cultured human CB CD34+ cells have a competitive advantage or disadvantage over untreated human CB CD34 + cells in terms of (1) short-term and longer term platelet recovery and (2) longer term hematological recovery. Our studies demonstrate that the TPO treated graft shows accelerated early platelet recovery without impairing the platelet engraftment of untreated CD34 + cells. Notably, this was followed by a dominant contribution to platelet production through the untreated CD34 + cell graft over the intermediate to longer term. Furthermore, although the contribution of the TPO treated graft to long-term hematological engraftment was reduced, the TPO treated and untreated grafts both contributed significantly to long-term chimerism in vivo.

show abstract

Section: Introductionmentioning

confidence: 99%

Thrombopoietin Treatment of One Graft in a Double Cord Blood Transplant Provides Early Platelet Recovery While Contributing to Long-Term Engraftment in NSG Mice

Brand

et al. 2015

Stem Cells and Development

Self Cite

View full text Add to dashboard Cite

show abstract

“…Delays in cryopreservation after the collection of cells may adversely affect cell viability [61]. A study by Guttridge et al [61] found that pre-cryopreservation storage time significantly affected the viability of CD34+ cells from UCB after cryopreservation, suggesting that extended pre-cryopreservation should be avoided.…”

Section: Additional Considerationsmentioning

confidence: 99%

“…A study by Guttridge et al [61] found that pre-cryopreservation storage time significantly affected the viability of CD34+ cells from UCB after cryopreservation, suggesting that extended pre-cryopreservation should be avoided. This finding is consistent with results of another study by Schwandt et al [62], which showed that the highest viability for cord blood cells was obtained when cells were cryopreserved directly after collection.…”

Section: Additional Considerationsmentioning

confidence: 99%

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Hornberger

McKenna

et al. 2019

Transfus Med Hemother

View full text Add to dashboard Cite

Hematopoietic stem cell (HSC) therapy is widely used to treat a growing number of hematological and non-hematological diseases. Cryopreservation of HSCs allows for cells to be transported from the site of processing to the site of clinical use, creates a larger window of time in which cells can be administered to patients, and allows sufficient time for quality control and regulatory testing. Currently, HSCs and other cell therapies conform to the same cryopreservation techniques as cells used for research purposes: cells are cryopreserved in dimethyl sulfoxide (DMSO) at a slow cooling rate. As a result, HSC therapy can result in numerous adverse symptoms in patients due to the infusion of DMSO. Efforts are being made to improve the cryopreservation of HSCs for clinical use. This review discusses advances in the cryopreservation of HSCs from 2007 to the present. The preclinical development of new cryoprotectants and new technology to eliminate cryoprotectants after thawing are discussed in detail. Additional cryopreservation considerations are included, such as cooling rate, storage temperature, and cell concentration. Preclinical cell assessment and quality control are discussed, as well as clinical studies from the past decade that focus on new cryopreservation protocols to improve patient outcomes.

show abstract

“…According to these studies, the extending of the time from collection to processing determined a decrease in cell viability mainly for granulocyte, while the viability of CD34 + cells seems to not to be affected [7,21,22,28,34]. Thus, interested in knowing if a larger number of CD34 + cells ensure maintaining a higher cell viability, we noticed that there was a very reduced positive correlation (r = 0.0782; P < 0.0001) between these parameters.…”

Section: Tablementioning

confidence: 80%

Factors which can influence the quality related to cell viability of the umbilical cord blood units

Dulugiac

Horeanga²,

Torcatoru³

et al. 2014

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Storage time affects umbilical cord blood viability

Abstract: This study demonstrates that extended precryopreservation storage adversely affects viability and should be avoided.

Cited by 28 publications

References 37 publications

Thrombopoietin Treatment of One Graft in a Double Cord Blood Transplant Provides Early Platelet Recovery While Contributing to Long-Term Engraftment in NSG Mice

Thrombopoietin Treatment of One Graft in a Double Cord Blood Transplant Provides Early Platelet Recovery While Contributing to Long-Term Engraftment in NSG Mice

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

Factors which can influence the quality related to cell viability of the umbilical cord blood units

Contact Info

Product

Resources

About